U.S. vaccines market to observe a noteworthy growth rate over 2017-2024, increasing implementation of vaccination programs to boost the product demand
Regulatory organizations have been making continuous efforts to generate awareness among the global populace regarding the advantages of vaccination. For instance, the U.S. Centers for Disease Control and Prevention (CDC) has inked guidelines to encourage people to take seasonal influenza vaccines for controlling and preventing the virus from spreading, especially in young children, the elderly, and pregnant women. In fact, CDC reports that post the implementation of vaccination programs, the percentage of people afflicted with influenza had decreased significantly across the U.S. As per estimates, U.S. covered a major share of the regional vaccines market revenue in 2016, pertaining to the numerous efforts undertaken by regulatory bodies.
Considering the myriad advantages that vaccines provide to improve an individual’s immunity system, researchers have been striving to conduct eminent study programs involving the methodology of combining vaccines with other cancer treatment methods such as radiations, chemotherapy, and Herceptin to enhance patient survival rate. Recently for instance, APAC vaccines market had witnessed an Australian company developing vaccines for breast and gastric cancer, the trials of which have depicted an affirmative result. The approval of this vaccine is likely to prove highly beneficial for cancer afflicted patients, and subsequently, is expected to provide a positive impetus to the regional vaccines market.
Notable behemoths across the vaccines market, namely, Merck & Co., AstraZeneca, Pfizer, Novartis, Bristol-Myers Squibb, CSL, Johnson & Johnson, Abbott, GlaxoSmithKline, Astellas Pharma, Sanofi Pasteur, Novavax, and Emergent BioSolutions, have been depicting considerable interest in R&D investments in order to brainstorm innovative products for disease prevention. With their efforts bearing fruit, vaccines market is expected to demonstrate a massive rise in its revenue graph over 2017-2024, additionally driven by commendable government initiatives to promote vaccination programs.
Author: jueekateThis author has published 1 articles so far. More info about the author is coming soon.